Interpace Biosciences, INC 10-Q quarterly reports
Quarterly reports, with unaudited financial statements and management’s discussion of the quarter just ended.
OID
Interpace Biosciences, Inc. filed its Q2 2026 Form 10-Q, detailing a revenue decrease but improved gross profit and operating income compared to the prior year, driven by a strategic shift following the loss of PancraGEN reimbursement.
OID
Interpace Biosciences reports a significant revenue decline and net income drop in Q3 2025, primarily due to the loss of Medicare coverage for its PancraGEN test, despite improving liquidity and reducing debt.
OID
Interpace Biosciences reported a net loss of $0.64 million in Q2 2025, primarily due to the loss of Medicare reimbursement for its PancraGEN test and associated restructuring costs.
OID
10-Q: Interpace Biosciences Reports Q1 2025 Results: Revenue Up, Faces PancraGEN Reimbursement Challenges
Interpace Biosciences reports increased revenue for Q1 2025 but faces challenges due to the loss of Medicare coverage for its PancraGEN test.
OID
Interpace Biosciences saw a significant increase in revenue and a return to profitability in the third quarter of 2024, driven by higher test volumes.
OID
Interpace Biosciences reported a significant increase in revenue and operating income for the second quarter of 2024, driven by higher test volumes.
OID
Interpace Biosciences saw a 4% increase in revenue to $10.3 million in the first quarter of 2024, driven by higher test volumes.